Ivabradine in Heart Failure: The Representativeness of SHIFT (Systolic Heart Failure Treatment With the IF Inhibitor Ivabradine Trial) in a Broad Population of Patients With Chronic Heart Failure [Original Articles]

Conclusions:
From the Swedish Heart Failure Registry, 14.2% of patients with HF were eligible for ivabradine. These patients more commonly were not receiving target β-blocker dose. Over time, a minority of patients became ineligible and an even smaller minority became eligible.

Source: Circulation: Heart Failure - September 13, 2017 Category: Cardiology Authors: Das, D., Savarese, G., Dahlstrom, U., Fu, M., Howlett, J., Ezekowitz, J. A., Lund, L. H. Tags: Clinical Studies, Heart Failure Original Articles Source Type: research